KR20210008393A - 세균 균주를 포함하는 조성물 - Google Patents

세균 균주를 포함하는 조성물 Download PDF

Info

Publication number
KR20210008393A
KR20210008393A KR1020207035244A KR20207035244A KR20210008393A KR 20210008393 A KR20210008393 A KR 20210008393A KR 1020207035244 A KR1020207035244 A KR 1020207035244A KR 20207035244 A KR20207035244 A KR 20207035244A KR 20210008393 A KR20210008393 A KR 20210008393A
Authority
KR
South Korea
Prior art keywords
composition
present
certain embodiments
compositions
ncimb
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020207035244A
Other languages
English (en)
Korean (ko)
Inventor
임케 엘리자베스 멀더
수아드 아메드
안나 에토레
사라 앤 레이드
테드 디난
존 크라이안
Original Assignee
4디 파마 리서치 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1810386.1A external-priority patent/GB201810386D0/en
Priority claimed from GBGB1813460.1A external-priority patent/GB201813460D0/en
Priority claimed from GBGB1817642.0A external-priority patent/GB201817642D0/en
Priority claimed from GBGB1820256.4A external-priority patent/GB201820256D0/en
Priority claimed from GBGB1820264.8A external-priority patent/GB201820264D0/en
Application filed by 4디 파마 리서치 리미티드 filed Critical 4디 파마 리서치 리미티드
Publication of KR20210008393A publication Critical patent/KR20210008393A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/308—Foods, ingredients or supplements having a functional effect on health having an effect on cancer prevention
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/324—Foods, ingredients or supplements having a functional effect on health having an effect on the immune system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C12R1/01—
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Pediatric Medicine (AREA)
  • Physiology (AREA)
  • Biochemistry (AREA)
KR1020207035244A 2018-05-11 2019-05-13 세균 균주를 포함하는 조성물 Ceased KR20210008393A (ko)

Applications Claiming Priority (15)

Application Number Priority Date Filing Date Title
EP18171893 2018-05-11
EP18171893.3 2018-05-11
EP18178136 2018-06-15
EP18178136.0 2018-06-15
GB1810386.1 2018-06-25
GBGB1810386.1A GB201810386D0 (en) 2018-06-25 2018-06-25 Compositions comprising bacterial strains
GBGB1813460.1A GB201813460D0 (en) 2018-08-17 2018-08-17 Compositions comprising bacterial strains
GB1813460.1 2018-08-17
GBGB1817642.0A GB201817642D0 (en) 2018-10-29 2018-10-29 Compositions comprising bacterial strains
GB1817642.0 2018-10-29
GB1820256.4 2018-12-12
GBGB1820256.4A GB201820256D0 (en) 2018-12-12 2018-12-12 Compositions comprising bacterial strains
GBGB1820264.8A GB201820264D0 (en) 2018-12-12 2018-12-12 Compositions comprising bacterial strains
GB1820264.8 2018-12-12
PCT/EP2019/062236 WO2019215345A1 (en) 2018-05-11 2019-05-13 Compositions comprising bacterial strains

Publications (1)

Publication Number Publication Date
KR20210008393A true KR20210008393A (ko) 2021-01-21

Family

ID=66597549

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020207035244A Ceased KR20210008393A (ko) 2018-05-11 2019-05-13 세균 균주를 포함하는 조성물
KR1020207035242A Ceased KR20210008391A (ko) 2018-05-11 2019-05-13 세균 균주를 포함하는 조성물

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020207035242A Ceased KR20210008391A (ko) 2018-05-11 2019-05-13 세균 균주를 포함하는 조성물

Country Status (23)

Country Link
US (3) US11419902B2 (https=)
EP (4) EP4066845A1 (https=)
JP (3) JP2021523895A (https=)
KR (2) KR20210008393A (https=)
CN (2) CN112601534A (https=)
AU (3) AU2019267170A1 (https=)
BR (1) BR112020022833A2 (https=)
CA (2) CA3099209A1 (https=)
CY (1) CY1125211T1 (https=)
DK (1) DK3743086T3 (https=)
ES (1) ES2916601T3 (https=)
HR (1) HRP20220578T1 (https=)
IL (1) IL278471B2 (https=)
LT (1) LT3743086T (https=)
MD (1) MD3743086T2 (https=)
MX (1) MX2020012061A (https=)
PL (1) PL3743086T3 (https=)
RS (1) RS63273B1 (https=)
SG (2) SG11202011031UA (https=)
SI (1) SI3743086T1 (https=)
SM (1) SMT202200217T1 (https=)
TW (2) TW202014513A (https=)
WO (2) WO2019215346A1 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA47439A (fr) 2017-01-31 2019-12-11 Univ Kansas State Cellules microbiennes, leurs procédés de production, et leurs utilisations
TWI812624B (zh) 2017-06-14 2023-08-21 南韓商希杰生物科技股份有限公司 包含細菌品系之組成物
WO2019079764A1 (en) 2017-10-20 2019-04-25 Ms Biotech, Inc. METHODS FOR PRODUCING PLANT MATERIALS EMITTED WITH MEGASPHAERA ELSDENII
SG11202011031UA (en) * 2018-05-11 2020-12-30 4D Pharma Res Ltd Compositions comprising bacterial strains
US11541105B2 (en) 2018-06-01 2023-01-03 The Research Foundation For The State University Of New York Compositions and methods for disrupting biofilm formation and maintenance
TW202038977A (zh) * 2018-12-12 2020-11-01 英商4D製藥研究有限公司 包含細菌菌株之組成物
WO2020120714A1 (en) * 2018-12-12 2020-06-18 4D Pharma Research Limited Compositions comprising bacterial strains
WO2021252861A1 (en) * 2020-06-11 2021-12-16 Evelo Biosciences, Inc. Compositions and methods for treating diseases and disorders using megasphaera sp
CN112980878B (zh) * 2021-02-04 2023-03-31 中国农业科学院兰州兽医研究所 Hdac8基因敲除的bhk-21细胞系及其构建方法和应用
CN112877275B (zh) * 2021-02-04 2023-03-31 中国农业科学院兰州兽医研究所 Hdac2基因敲除的bhk-21细胞系及其构建方法和应用
WO2023208225A1 (zh) 2022-04-28 2023-11-02 慕恩（广州）生物科技有限公司 药物组合物、巨球型菌及其应用
WO2023208223A1 (zh) 2022-04-28 2023-11-02 慕恩（广州）生物科技有限公司 药物组合物、巨球型菌及其应用
KR102551061B1 (ko) * 2022-05-26 2023-07-03 중앙대학교 산학협력단 Saha를 유효성분으로 포함하는 살모넬라 속 균주에 의한 바이오필름 생성 저해용 조성물
CN117018036B (zh) * 2023-07-28 2025-09-05 深圳未知君生物科技有限公司 巨球形菌属细菌在制备治疗癌症的药物中的应用

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5557520A (en) * 1978-10-26 1980-04-28 Nisshin Flour Milling Co Ltd Preparation of carcinostatic substance
WO2002080947A1 (fr) 2001-04-06 2002-10-17 Kyodoken Institute For Animal Science Research & Development Compositions contenant une bacterie pouvant convertir de l'acide lactique en acide butyrique, et methode utilisant ces compositions pour prevenir ou traiter l'hyperlactacidemie dans le systeme digestif ou le cancer du colon
GB0127916D0 (en) 2001-11-21 2002-01-16 Rowett Res Inst Method
US20040005304A1 (en) 2002-07-08 2004-01-08 Mak Wood, Inc. Novel compositions and methods for treating neurological disorders and associated gastrointestinal conditions
GB0307026D0 (en) * 2003-03-27 2003-04-30 Rowett Res Inst Bacterial supplement
CA2535889A1 (en) 2003-08-29 2005-03-17 Aton Pharma, Inc. Combination methods of treating cancer
GB201112091D0 (en) 2011-07-14 2011-08-31 Gt Biolog Ltd Bacterial strains isolated from pigs
GB201117313D0 (en) 2011-10-07 2011-11-16 Gt Biolog Ltd Bacterium for use in medicine
CA3212215A1 (en) 2012-11-23 2014-05-30 Seres Therapeutics, Inc. Synergistic bacterial compositions and methods of production and use thereof
HK1218560A1 (zh) 2013-02-04 2017-02-24 Seres Therapeutics, Inc. 组成与方法
GB201306536D0 (en) 2013-04-10 2013-05-22 Gt Biolog Ltd Polypeptide and immune modulation
EP3021853A1 (en) * 2013-07-18 2016-05-25 Baylor College Of Medicine Method of enhancing potency of immune cells
CN104415060A (zh) * 2013-08-30 2015-03-18 深圳华大基因科技有限公司 可食用组合物及其制备方法和用途
US10203329B2 (en) * 2013-09-12 2019-02-12 The Johns Hopkins University Biofilm formation to define risk for colon cancer
EP3074027B1 (en) 2013-11-25 2024-12-18 Seres Therapeutics, Inc. Synergistic bacterial compositions and methods of production and use thereof
US9650654B2 (en) * 2014-06-25 2017-05-16 William Marsh Rice University Making C4+ products in bacteria
US10366793B2 (en) * 2014-10-21 2019-07-30 uBiome, Inc. Method and system for characterizing microorganism-related conditions
WO2016073381A1 (en) * 2014-11-03 2016-05-12 Cerus Corporation Compositions and methods for improved car-t cell therapies
MA41020A (fr) * 2014-11-25 2017-10-03 Evelo Biosciences Inc Compositions probiotiques et prébiotiques, et leurs procédés d'utilisation pour la modulation du microbiome
CN107405321A (zh) * 2015-01-23 2017-11-28 坦普尔大学 短链脂肪酸在癌症预防中的应用
US20180078587A1 (en) 2015-03-18 2018-03-22 Trustees Of Tufts College Compositions and methods for preventing colorectal cancer
MA41060B1 (fr) 2015-06-15 2019-11-29 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
HK1254843B (zh) * 2015-11-20 2020-04-17 希杰生物科技株式会社 包含细菌菌株的组合物
US20190247447A1 (en) * 2015-11-24 2019-08-15 Seres Therapeutics, Inc. Designed bacterial compositions
WO2017122197A1 (en) * 2016-01-11 2017-07-20 3Plw Ltd. Lactic acid-utilizing bacteria genetically modified to secrete polysaccharide-degrading enzymes
CN107028985A (zh) * 2016-02-04 2017-08-11 深圳华大基因研究院 厚壁菌类益生菌在预防和/或治疗糖尿病及其相关疾病中的应用
US20190125808A1 (en) * 2016-03-30 2019-05-02 The Trustees Of Columbia University In The City Of New York Methods of preventing, treating and detecting colorectal cancer using butyrate producing bacteria
US9999641B2 (en) * 2016-06-14 2018-06-19 Vedanta Biosciences, Inc. Treatment of clostridium difficile infection
JP7542946B2 (ja) * 2016-09-27 2024-09-02 ボード オブ リージェンツ， ザ ユニヴァーシティー オブ テキサス システム マイクロバイオームをモジュレートすることにより、免疫チェックポイント遮断療法を増強するための方法
US11571446B2 (en) 2016-11-18 2023-02-07 Sanford Bumham Prebys Medical Discovery Institute Gut microbiota and treatment of cancer
US20190314427A1 (en) 2016-12-16 2019-10-17 Evelo Biosciences, Inc. Methods of treating cancer using parabacteroides
WO2018112365A2 (en) 2016-12-16 2018-06-21 Evelo Biosciences, Inc. Methods of treating colorectal cancer and melanoma using parabacteroides goldsteinii
PL3600363T3 (pl) * 2017-06-14 2021-06-14 4D Pharma Research Limited Kompozycje zawierające szczepy bakteryjne
TWI812624B (zh) * 2017-06-14 2023-08-21 南韓商希杰生物科技股份有限公司 包含細菌品系之組成物
SG11202011031UA (en) * 2018-05-11 2020-12-30 4D Pharma Res Ltd Compositions comprising bacterial strains
WO2020120714A1 (en) * 2018-12-12 2020-06-18 4D Pharma Research Limited Compositions comprising bacterial strains
TW202038977A (zh) * 2018-12-12 2020-11-01 英商4D製藥研究有限公司 包含細菌菌株之組成物

Also Published As

Publication number Publication date
TW202011975A (zh) 2020-04-01
JP2021523895A (ja) 2021-09-09
ES2916601T3 (es) 2022-07-04
SMT202200217T1 (it) 2022-07-21
SG11202011028SA (en) 2020-12-30
MD3743086T2 (ro) 2022-12-31
DK3743086T3 (da) 2022-05-02
EP3743086A1 (en) 2020-12-02
EP3790564A1 (en) 2021-03-17
AU2023200562A1 (en) 2023-03-02
IL278471B2 (en) 2023-08-01
IL278471A (https=) 2020-12-31
TW202014513A (zh) 2020-04-16
US20210052671A1 (en) 2021-02-25
US20210275605A1 (en) 2021-09-09
HRP20220578T1 (hr) 2022-09-16
US20230158083A1 (en) 2023-05-25
JP7058449B2 (ja) 2022-04-22
BR112020022833A2 (pt) 2021-02-02
CN112601534A (zh) 2021-04-02
AU2019267171A1 (en) 2021-01-07
CN112512539A (zh) 2021-03-16
MX2020012061A (es) 2022-10-13
KR20210008391A (ko) 2021-01-21
LT3743086T (lt) 2022-06-10
SG11202011031UA (en) 2020-12-30
JP2022088631A (ja) 2022-06-14
WO2019215346A1 (en) 2019-11-14
CA3098971A1 (en) 2019-11-14
WO2019215345A1 (en) 2019-11-14
EP3743086B1 (en) 2022-03-16
EP4056192A1 (en) 2022-09-14
CA3099209A1 (en) 2019-11-14
US11419902B2 (en) 2022-08-23
SI3743086T1 (sl) 2022-05-31
AU2019267170A1 (en) 2021-01-07
RS63273B1 (sr) 2022-06-30
EP4066845A1 (en) 2022-10-05
JP2021517560A (ja) 2021-07-26
IL278471B1 (en) 2023-04-01
PL3743086T3 (pl) 2022-06-20
CY1125211T1 (el) 2024-02-16

Similar Documents

Publication Publication Date Title
KR20210008393A (ko) 세균 균주를 포함하는 조성물
US11040075B2 (en) Compositions comprising bacterial strains
US11433106B2 (en) Compositions comprising bacterial strains
US11389493B2 (en) Compositions comprising bacterial strains
US20220265733A1 (en) Compositions comprising bacterial strains
US20210275606A1 (en) Compositions comprising bacterial strains
JP2021522160A (ja) 細菌株を含む組成物
HK40023525A (en) Compositions comprising bacterial strains
HK1240831B (en) Compositions comprising bacterial strains
HK1240831A1 (en) Compositions comprising bacterial strains

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D13-X000 Search requested

St.27 status event code: A-1-2-D10-D13-srh-X000

D14-X000 Search report completed

St.27 status event code: A-1-2-D10-D14-srh-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

B15 Application refused following examination

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B15-EXM-PE0601 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601